| Biological Information | |
|---|---|
| Background Information: | The Abl tyrosine kinase inhibitor STI571 (Gleevec™) is an effective therapy for stable-phase chronic myeloid leukemia patients. Many patients responding to STI571 later relapse, due to a reactivation of Bcr-Abl activity. In certain cases this appears to correlate with the presence of the H396P mutation, which confers resistance to drug binding due to steric interference. (Corbin AS. et al, Blood, (2002); 101:4611-4614 and La Rosee P. et al, Cancer Research; 62:7149-7153). |
| Target Class: | Kinase |
| Accession Number: | U07563 |
| Target Name: | Abl |
| Target Aliases: | ABL1, JTK7, ABL, p150, vABL, cABL, bcr/abl |
| Target Species: | Human |
| Usage | |
| Product Type: | Enzymes |
| Application: | Drug Discovery & Development |
| Storage Conditions: | 6 months at -70°C |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
Abl (H396P), active
10 µg of active Abl (H396P). N-terminal 6His-tagged recombinant, human Abl, amino acids 27-end containing the H396P mutation.
Datasheets
14-750x Datasheet
View Document